argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
Watch Argenx's latest callArgenx (Euronext:ARGX) Q3 2026 Earnings Call · Replay · Oct 22Read the transcript of Argenx (Euronext:ARGX) Q3 2026 Earnings CallThe original release is unavailable here.
Earlier from Argenx
- argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
- argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
- argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
- argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
- argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
Later from Argenx
- argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
- argenx to Present at Upcoming Investor Conferences
- FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations
- argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
- argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
Follow Argenx into a list and get an email when it puts out news.
Follow Argenx